Shopping Cart
- Remove All
Your shopping cart is currently empty
(49)
By Tag- C-His-Avi
- N-His(5)
- N-6xHis(3)
- N-GST(2)
- C-6xHis(1)
- N-His-Avi(1)
Filter
Applied FilterClear all
By Tag By Expression System- HEK293 Cells(38)
- E. coli(22)
- Baculovirus Insect Cells(1)
By Species- Human(61)
By SPR-compatible Buffer- Ready-to-use(51)
- Buffer exchange required(9)
- Buffer-exchangeable(1)
Filter
Search Result
Results for "
cfc 2
" in TargetMol Product Catalog- Recombinant Protein61
- Antibody Products1
CompareRASK2, KRAS2, Ki-Ras, c-K-ras, CFC2
TMPJ-00510
KRAS Protein, Human, Recombinant (G12C, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 26 KDa and the accession number is AAH13572.1.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, KRAS2, Ki-Ras, c-K-ras, CFC2
TMPJ-00511
KRAS Protein, Human, Recombinant (G12V, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25-30 KDa and the accession number is AAH13572.1.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPU-00001
Expression system: E. coli
Length: 1-169, Partial
Activity: BLI
Length: 1-169, Partial
Activity: BLI
Inquiry
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04113
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04116
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06056
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06138
Expression system: E. coli
Length: 2-185, Full Length of Mature Protein
Activity: Not Tested
Length: 2-185, Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06345
Expression system: E. coli
Length: 2-185 (mutation), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (mutation), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01399
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01400
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01401
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01402
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01403
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01404
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01407
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01408
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01427
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01428
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01429
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01430
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01431
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01432
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01433
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01434
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
Go to page 1
Page of 2
Product Comparison
| Product |
|---|
| Bioactive |
| Species |
| Expression System |
| Tag |
| Accession Number |
| Amino Acid |
| Construction |
| Molecular Weight |
| Endotoxin |
| Formulation |
| Reconstitution |
| Stability & Storage |
| Shipping |
| Research Background |
| Size |
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.